About the 2022 Country 2 Country 4 Cancer Ride

After five successful years of the Country 2 Country 4 Cancer (C2C4C) ride, the 2022 edition of C2C4C will feature more than 150 Bristol Myers Squibb employees riding in-country routes in Germany, Switzerland, Italy, France, Spain, Belgium and the United Kingdom for nearly 3,000 kilometers from 2-19 September. Six teams will feature riders participating from 16 countries including Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Ireland and the United Kingdom. The goal of C2C4C is to raise awareness for cancer research and European cancer organisations who are members of the UICC.

Raising Funds for the association AKTIV Mot Kreft in Norway

According to the WHO, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. This is why the SpeeRaisers Team (riders of the 2022 year) are riding in support of the association AKTIV Mot Kreft (AKTIV Against Cancer) its mission to support cancer patients. Encourage your colleagues, families and friends to donate, as cancer affects us all.

Who Are the Riders

The participants are novice riders, who have committed themselves to 5 months of intensive training to complete their portion of the ride. Some are cancer survivors, others have witnessed the devastating impact of cancer on friends and family. Their kilometers will help raise funds to fight against cancer by supporting the association for AKTIV Mot Kreft (AKTIV Against Cancer) a member of the Union for International Cancer Control.

About BMS

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.

About the UICC

The Union for International Cancer Control (UICC)is the largest global membership organization dedicated to the fight against cancer. Founded in Geneva in 1933, UICC has some 1,180 member organisations in 172 countries. UICC’s mission is to both unite and support the cancer community in its efforts to reduce the global cancer burden, promote greater equity and ensure that cancer control remains a priority on the global health and development agenda.